Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trp-2 mRNA constructs
- Development stage
- Unknown
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics, Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Intradermal, Ex Vivo Dendritic Cell Transfer
01
Overview
TRP-2 mRNA constructs are investigational mRNA-based therapeutics encoding the antigen tyrosinase-related protein 2 (TRP-2, also known as dopachrome tautomerase), which is a melanocyte differentiation antigen involved in melanin synthesis. These constructs are primarily developed as cancer vaccines and immunotherapies for malignant melanoma. The mechanism of action is induction of immune responses (especially cytotoxic T lymphocyte activation) against tumor cells expressing TRP-2, aiming to enhance anti-tumor immunity. TRP-2 mRNA is commonly delivered into dendritic cells ex vivo (typically autologous Langerhans-type dendritic cells) by electroporation or formulated into nanoparticles for in vivo administration. This approach leverages antigen presentation to stimulate melanoma-specific immunity and is currently in early-phase clinical development[2][4][5].
- Other names
- TRP2 mRNATRP-2 mRNATRP 2 mRNAtyrosinase-related protein 2 mRNA vaccinedopachrome tautomerase mRNA vaccine
02
Targets
TYRP2 (Tyrosinase-related Protein 2)
Beyond the preview
Go deeper on trp-2 mRNA constructs.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trp-2 mRNA constructs.